Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Tokyo
  • Sector: Health Care
  • Industry: Health Care Facilities & Svcs
  • Sub-Industry: Health Care Services

Linical Co Ltd

+ Add to Watchlist

2183:JP

974.0 JPY 11.0 1.12%

As of 01:00:00 ET on 02/27/2015.

Snapshot for Linical Co Ltd (2183)

Open: 974.0 Day's Range: 967.0 - 978.0 Volume: 24,100
Previous Close: 985.0 52wk Range: 776.0 - 1,053.0 1-Yr Rtn: +9.60%

Stock Chart for 2183

No chart data available.
  • 2183:JP 974.0
  • 1D
  • 1M
  • 1Y
985.0
Interactive 2183 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 2183

Current P/E Ratio (ttm) 25.8355
Estimated P/E(03/2015) 17.9044
Relative P/E vs. TPX 1.4883
Earnings Per Share (JPY) (ttm) 37.7000
Est. EPS (JPY) (03/2015) 54.4000
Est. PEG Ratio -
Market Cap (M JPY) 12,048.38
Shares Outstanding (M) 12.37
30 Day Average Volume 16,117
Price/Book (mrq) 5.8997
Price/Sale (ttm) 2.6228
Dividend Indicated Gross Yield 1.44%
Cash Dividend (JPY) 14.0000
Dividend Ex-Date 03/27/2015
5 Year Dividend Growth 4.94%
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 2183

  • Revenue
  • Net Income (M/JPY)
  • Profit Margin (%)

Company Profile & Key Executives for 2183

LINICAL CO LTD is a Contract Research Organization (CRO) for Pharmaceutical Companies. The company specializes in Clinical Research Associate of Phase II and Phase III, while conducting other clinical trial related services such as Quality Management and Consulting.

Kazuhiro HatanoPresident/FounderKeigo TsujimotoExecutive Vice President
Akihiro TakahashiSenior Managing Director/CFOJun KawaiSenior Managing Director
More Company Profile & Key Executives for 2183

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil